REFERENCES
- Baruchel A, Leblanc T, Schaison G. Pathology of acute lymphoblastic leukemias. Pediatric Hematology, ed 2, J S Lilleyman, I M Hann, V S Blanchette. Churchill Livingstone, Harcourt, London 1999; 519–536
- Silverman L B, Sallan S E. Acute lymhoblastic leukemia. Nathan and Oski's Hematology of Infancy and Childhood, ed 6, D G Nathan, S H Orkin, D Ginsburg, A T Look. WB Saunders, Philadelphia 2003; 1135–1166
- Saito M, Asakura H, Jokaji H, et al. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol 1989; 32: 20–23, [INFOTRIEVE], [CSA]
- Mazzucconi M G, Gugliotta L, Leone G, et al. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymhoblastic leukemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Blood Coagul Fibrinolysis. 1994; 5: 23–28, [INFOTRIEVE], [CSA]
- Leone G, Gugliotta L, Mazzucconi M G, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study. Thromb Haemost 1993; 69: 12–15, [INFOTRIEVE], [CSA]
- Chabner B A, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs. Wiilliams Hematology, ed 6., E Beutler, M A Lichtman, B S Coller, T J Kipps, U Seligsohn. McGraw-Hill, New York 2001; 185–200
- Priest J R, Ramsay N K, Steinherz P G, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984–989, [INFOTRIEVE], [CROSSREF], [CSA]
- Steinherz P G, Miller L P, Ghavimi F, et al. Dural sinus thrombosis in children with acute lymphoblastic leukemia. JAMA 1981; 246: 2837–2839, [INFOTRIEVE], [CROSSREF], [CSA]
- Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. Br J Haematol 1990; 74: 465–470, [INFOTRIEVE], [CSA]
- Nowak-Gottl U, Kuhn N, Wolff J E, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996; 56: 35–38, [INFOTRIEVE], [CSA]
- Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531–539, [INFOTRIEVE], [CSA]
- Levi M, Peters M, Büller H R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005; 33: 883–890, [INFOTRIEVE], [CROSSREF], [CSA]
- Mathew P, Winter S S, Frost J D, Hanrahan J, et al. Novel applications of recombinant factor VIIa for the management of pediatric coagulopathic diseases. J Pediatr Hematol Oncol 2003; 25: 499–502, [INFOTRIEVE], [CROSSREF], [CSA]
- Zulfikar B, Kayran S M. Succesful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15: 261–263, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hicks K, Peng D, Gajewski J L. Treatment of difuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975–978, [INFOTRIEVE], [CROSSREF], [CSA]
- White B, Martin M, Kelleher S, et al. Succesful use of recombinant FVIIa (NovoSeven) in the management of pulmonary haemorrhage secondary to Aspergillus infection in a patient with leukemia and acquired FVII deficiency. Br J Haematol 1999; 106: 254–255, [INFOTRIEVE], [CROSSREF], [CSA]
- Blatt J, Gold S H, Wiley J M, et al. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001; 28: 405–407, [INFOTRIEVE], [CROSSREF], [CSA]
- Broderick J, Brott T G, Duldrer J E, et al. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day-mortality. Stroke 1993; 24: 987–993, [PUBMED], [INFOTRIEVE], [CSA]
- Sorensen B, Johansen P, Nielsen G L, et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003; 14: 469–477, [INFOTRIEVE], [CROSSREF], [CSA]
- Mayer S A, Brun N C, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–785, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Halton J M, Mitchell L G, Vegh P, et al. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol 1994; 47: 157–161, [INFOTRIEVE], [CSA]
- Mariani G, Testa M G, Di Paolantonio T, et al. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131–136, [INFOTRIEVE], [CROSSREF], [CSA]